In my understanding, that is what the company told on the 21st of Dec, money for PBT2 is coming from elsewhere, not from cash ATH has: "Alterity intends to direct new resources to the project with no impact on its lead commercialisation program for ATH434, which is advancing to Phase 2 in Multiple System Atrophy, a Parkinsonian disorder with no approved therapy".
And there is the needed money for this purpose: Antimicrobial Resistance Research & Development - AMR Action Fund. They have over 1 billion to start with. There are no signs that there would be any negotiations but to me, it looks like ATH needs AMR and AMR needs ATH. But a single big pharma for sure has more money than AMR, so there is also some competition, perhaps. Behind AMR there are over 20 pharma companies and each of them has an interest in PBT2, I would believe.
ATH Price at posting:
3.2¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)